A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

This study is testing a new antibody-drug conjugate (ADC) called HWK-016 — a targeted treatment that delivers chemotherapy directly to cancer cells carrying the protein MUC16 (also known as CA-125) — in patients with advanced endometrial (uterine) or ovarian cancer. **You may be eligible if...** - You have been diagnosed with advanced endometrial cancer or ovarian cancer - For the combination therapy portion: you must have ovarian cancer **You may NOT be eligible if...** - You have uncontrolled cancer spread to the brain or spinal fluid - You have a history of cancer spreading to the lining around the brain (carcinomatous meningitis) - You have an active, uncontrolled serious infection - You have corneal eye disease or have had a cornea transplant - You have unresolved significant side effects from previous treatments - You have significant heart disease or abnormal heart rhythms on ECG - You have a history of lung inflammation (pneumonitis or interstitial lung disease) - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.